SeekingAlpha · Aug 7, 2026
OmniAb, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by OmniAb, Inc.
OA
NASDAQ · OABIW
OmniAb, Inc.
Healthcare · Biotechnology
$0.23
Down-$0.05 (-22.58%)
Updated Aug 25, 2026, 2:41 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 14.42M
- P/E ratio
- -3.9
- Dividend yield
- 0.00%
- 52-week range
- $0.04 – $0.40
- Volume
- 12.74K
- Avg. volume
- 30.96K
Price performance
OABIW price history
1M range · 12 trading sessions · Daily adjusted prices
OABIW closed at $0.23 after 12 trading sessions, up 178.78% for the selected period.
- Last close
- $0.23
- Period change
- +178.78%
- Period low
- $0.05
- Period high
- $0.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | $0.2339 | $0.2339 | $0.18 | $0.2325 | 12.74K |
| Aug 21, 2026 | $0.25 | $0.25 | $0.155 | $0.155 | 12.78K |
| Aug 20, 2026 | $0.221 | $0.3025 | $0.221 | $0.2845 | 39.46K |
| Aug 19, 2026 | $0.2175 | $0.2541 | $0.19 | $0.19 | 24.17K |
| Aug 18, 2026 | $0.263 | $0.3147 | $0.204 | $0.2275 | 15.46K |
| Aug 17, 2026 | $0.22 | $0.3999 | $0.20 | $0.2151 | 385.79K |
| Aug 13, 2026 | $0.08 | $0.0851 | $0.08 | $0.0851 | 7.2K |
| Aug 11, 2026 | $0.08 | $0.08 | $0.07 | $0.0795 | 30.17K |
| Aug 10, 2026 | $0.08 | $0.08 | $0.08 | $0.08 | 175 |
| Aug 7, 2026 | $0.05 | $0.08 | $0.05 | $0.074 | 30.84K |
| Aug 6, 2026 | $0.045 | $0.0451 | $0.045 | $0.0451 | 201 |
| Jul 28, 2026 | $0.061 | $0.088 | $0.04 | $0.0834 | 30.32K |
Latest OABIW news
The latest Smart Investors Daily articles mentioning OABIW.
Stock researchCompany · Overview
OABIW research
Overview
Company profile and research snapshot.
Company profile
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 7, 2026
OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript
OmniAb, Inc. (OABI) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsKurt Gustafson - Executive VP of Finance & CFOMatthew Foehr -...
Yahoo · Jul 13, 2026
OmniAb Names Amechi Nwachuku Chief Operating Officer
EMERYVILLE, Calif., July 13, 2026--OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration®, OmniAb’s proprietary, innovative high-throughp
Yahoo · Mar 31, 2026
Here Is Why You Should Not Ignore OmniAb Inc. (OABI)
OmniAb Inc. (NASDAQ:OABI) is one of the 10 best penny stocks that could triple your money. On March 5, OmniAb Inc. (NASDAQ:OABI) reported fourth-quarter revenue of $8.4 million, coming in below consensus estimates of $9.0 million. The company closed 2025 with a growing base of 107 active partners and a growing portfolio consisting of 407 […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
